InsidersTradesSigma
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
5
Disclosed sells
0
T+90 hit rate
43%
T+90 mean return
-11.9%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Zeskind Benjamin J., Chairman & CEO. Officer active across 1 company, notably Immuneering Corp. Cumulatively, 10 filings have been recorded. Split: 5 buys · 0 sell. Total volume traded: €153k. Activity tracked since 13 September 2021. The latest transaction was filed on 19 March 2024 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations10 total
2,400 sharesClass A Common StockSEC:0001790340-26-000078:0
Ideal exit: 20 Mar 2027 (T+270)
20,000 shares@ US$2.766329.7% of flowClass A Common StockSEC:0001790340-24-000026:0
Ideal exit: 14 Dec 2024 (T+270)
2,500 shares@ US$3.014.1% of flowClass A Common StockSEC:0001415889-22-012975:0
2,000 shares@ US$3.010.0017% mcap4.9% of flowClass A Common StockSEC:0001415889-22-004065:0
3,000 shares@ US$8.020.0065% mcap19.2% of flowClass A Common StockSEC:0001415889-22-003324:0
Ideal exit: 18 Dec 2022 (T+270)
2,000 shares@ US$3.010.0016% mcap4.7% of flowClass A Common StockSEC:0001415889-22-002061:0
2,083 shares@ US$22.86723.5% of flowClass A Common StockSEC:0001415889-21-004382
Ideal exit: 10 Jun 2022 (T+270)
2,083 shares@ US$22.8670.012% mcap35.6% of flowClass A Common StockSEC:0001415889-21-004382:0
Ideal exit: 10 Jun 2022 (T+270)
49,099 sharesClass A Common StockSEC:0001104659-21-099741:0
49,099 sharesClass A Common StockSEC:0001104659-21-099741
10 of 10 declarations
About Zeskind Benjamin J.
Benjamin J. Zeskind is the President and CEO of Immuneering Corp. He leads the company with a strategic vision focused on innovation and growth. Zeskind brings significant expertise in business management and product development, thus contributing to Immuneering's mission to provide advanced therapeutic solutions. His leadership is essential for navigating the dynamic biotechnology market.
